License agreement with iPS Academia Japan, Inc.

On March 22, 2023 Thyas reported that it has signed a license agreement with iPS Academia Japan, Inc. ("iPS-AJ"; Sakyo-ku, Kyoto) in which iPS-AJ grants Thyas a non-exclusive license of the patents relating to iPS cell reprogramming technologies and an exclusive license of the patents relating to iPSC-to-T cell differentiation technologies applicable to the autologous iPSC-derived T cell therapies for treatments of antigen-specific tumors and infectious diseases worldwide (Press release, Thyas , MAR 22, 2023, View Source [SID1234629208]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

iPS-AJ is a technology licensing organization of Kyoto University.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!